Q3’23: Xtampza ER Prescription Metrics

Total Xtampza Prescriptions

(thousands)



Prescriptions by Dosage Strength

(thousands)



Total Morphine Milligram Equivalents (MMEs)

(thousands)



MMEs Per Prescription

(thousands)



Sources: 1: IQVIA NPA, October 2023; 2: IQVIA Xponent, October 2023

Notes: MA prescription volume representative of current ‘primary’ (date of publication) HCP state address, HCPs may have multiple addresses and HCP state addresses may change; MME are calculated based upon 1.5 conversion factor for oxycodone multiplied by the finished product weight (dose strength)

Q2’23: Xtampza ER Prescription Metrics

Total Xtampza Prescriptions

(thousands)



Prescriptions by Dosage Strength

(thousands)



Total Morphine Milligram Equivalents (MMEs)

(thousands)



MMEs Per Prescription

(thousands)



Sources: 1: IQVIA NPA, June 2023; 2: IQVIA Xponent, June 2023

Notes: MA prescription volume representative of current ‘primary’ (date of publication) HCP state address, HCPs may have multiple addresses and HCP state addresses may change; MME are calculated based upon 1.5 conversion factor for oxycodone multiplied by the finished product weight (dose strength)

Q1’23: Xtampza ER Prescription Metrics

Total Xtampza Prescriptions

(thousands)



Prescriptions by Dosage Strength

(thousands)



Total Morphine Milligram Equivalents (MMEs)

(thousands)



MMEs Per Prescription

(thousands)



Sources: 1: IQVIA NPA, March 2023; 2: IQVIA Xponent, March 2023

Notes: MA prescription volume representative of current ‘primary’ (date of publication) HCP state address, HCPs may have multiple addresses and HCP state addresses may change; MME are calculated based upon 1.5 conversion factor for oxycodone multiplied by the finished product weight (dose strength)

Q4’22: Xtampza ER Prescription Metrics

Total Xtampza Prescriptions

(thousands)



Prescriptions by Dosage Strength

(thousands)



Total Morphine Milligram Equivalents (MMEs)

(thousands)



MMEs Per Prescription

(thousands)



Sources: 1: IQVIA NPA, December 2022; 2: IQVIA Xponent, December 2022

Notes: MA prescription volume representative of current ‘primary’ (date of publication) HCP state address, HCPs may have multiple addresses and HCP state addresses may change; MME are calculated based upon 1.5 conversion factor for oxycodone multiplied by the finished product weight (dose strength)

Q3’22: Xtampza ER Prescription Metrics

Total Xtampza Prescriptions

(thousands)



Prescriptions by Dosage Strength

(thousands)



Total Morphine Milligram Equivalents (MMEs)

(thousands)



MMEs Per Prescription

(thousands)



Sources: 1: IQVIA NPA, September 2022; 2: IQVIA Xponent, September 2022

Notes: MA prescription volume representative of current ‘primary’ (date of publication) HCP state address, HCPs may have multiple addresses and HCP state addresses may change; MME are calculated based upon 1.5 conversion factor for oxycodone multiplied by the finished product weight (dose strength)

Q2’22: Xtampza ER Prescription Metrics

Total Xtampza Prescriptions

(thousands)



Prescriptions by Dosage Strength

(thousands)



Total Morphine Milligram Equivalents (MMEs)

(thousands)



MMEs Per Prescription

(thousands)



Sources: 1: IQVIA NPA, June 2022; 2: IQVIA Xponent, June 2022

Notes: MA prescription volume representative of current ‘primary’ (date of publication) HCP state address, HCPs may have multiple addresses and HCP state addresses may change; MME are calculated based upon 1.5 conversion factor for oxycodone multiplied by the finished product weight (dose strength)

Q1’22: Xtampza ER Prescription Metrics

Total Xtampza Prescriptions

(thousands)



Prescriptions by Dosage Strength

(thousands)



Total Morphine Milligram Equivalents (MMEs)

(thousands)



MMEs Per Prescription

(thousands)



Sources: 1: IQVIA NPA, March 2022; 2: IQVIA Xponent, March 2022

Notes: MA prescription volume representative of current ‘primary’ (date of publication) HCP state address, HCPs may have multiple addresses and HCP state addresses may change; MME are calculated based upon 1.5 conversion factor for oxycodone multiplied by the finished product weight (dose strength)